K
KPTI
Karyopharm Therapeutics Inc
8.97
+0.81+9.93%After Hours: 9.15 +0.18 +2.01%18:39 05/26 EDT
OPEN/PREV CLOSE8.30/8.16
TODAY RANGE8.22-9.06
VOL570.69K
MARKET CAP203.29M
52 WEEK RANGE3.650-10.99
AVG VOL (3M)940.30K
% TURNOVER2.52%
TURNOVER--
P/E (TTM)-0.6043
% RANGE10.23%
EPS(TTM)-14.8444
P/E(FORWARD)-2.1932
P/B-0.7612
BVPS-11.7834
DIVIDEND--
P/S1.124
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP193.43M
SHARES OUTSTANDING22.66M
NEXT EARNINGS08/10-08/14
FREE FLOAT21.56M
LOT SIZE1
EX-DATE02/26/2025
News
Press Releases
Financial Reports
Profile
TipRanks·6d ago
Karyopharm (KPTI) Leans on SENTRY in Pivotal Call
Benzinga·05/19 12:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Simply Wall St·05/15 23:41
Karyopharm Therapeutics (KPTI) Quarterly Loss Deepens Reinforcing Bearish Profitability Concerns
TipRanks·05/15 15:26
Leerink Partners Sticks to Its Hold Rating for Karyopharm Therapeutics (KPTI)
TipRanks·05/15 11:48
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanks·05/15 00:20
Karyopharm Earnings Call: Trial Wins, Cash Questions
Seeking Alpha·05/14 19:01
Karyopharm outlines $130M-$150M 2026 revenue outlook as it prepares mid-2026 XPORT-EC-042 readout
Benzinga·05/14 13:37
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
TipRanks·05/14 12:06
Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)
TipRanks·05/14 12:04
Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M
Reuters·05/14 11:42
Karyopharm Q1 net loss narrows
Seeking Alpha·05/14 11:39
Karyopharm Therapeutics GAAP EPS of -$1.24 beats by $0.25, revenue of $35.07M beats by $3.67M
Same Industry
Name/Symbol
Change%
Price